Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same author

In sphincter of Oddi patients, amelioration of pain is primarily associated with common bile duct dilation rather than hepatobiliary scintigraphy excretion time or alanine amino transferase - a single centre, retrospective study.

Clinical physiology and functional imaging·2026
Same author

Expert panel perspectives on improving the diagnosis and management of metabolic dysfunction-associated steatohepatitis in Denmark.

Scandinavian journal of gastroenterology·2026
Same author

LC-MS/MS of PEth in whole blood: implementation in routine clinical chemistry.

Practical laboratory medicine·2026
Same author

Liver support systems for adults with acute liver failure.

The Cochrane database of systematic reviews·2026
Same author

Magnetic resonance imaging-derived extracellular volume fraction mapping in metabolic dysfunction-associated steatotic liver disease reveals subclinical cardiac remodelling.

Scientific reports·2026

Related Experiment Video

Updated: May 25, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
03:07

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Tranexamic acid for upper gastrointestinal bleeding.

Lise Lotte Gluud1, Sarah Louise Klingenberg, Ebbe Langholz

  • 1Department of InternalMedicine, Gentofte UniversityHospital, Hellerup,Denmark.liselottegluud@yahoo.dk.

The Cochrane Database of Systematic Reviews
|January 20, 2012
PubMed
Summary
This summary is machine-generated.

Tranexamic acid may reduce mortality in upper gastrointestinal bleeding, but this benefit was not consistently confirmed. Further research is needed to determine its routine use and optimal application.

Related Experiment Videos

Last Updated: May 25, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
03:07

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

Published on: July 12, 2024

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Critical Care Medicine

Background:

  • Tranexamic acid is an antifibrinolytic agent used to reduce hemorrhage.
  • Previous reviews suggested a potential mortality benefit of tranexamic acid.
  • This review updates evidence on tranexamic acid for upper gastrointestinal bleeding.

Purpose of the Study:

  • To assess the efficacy and safety of tranexamic acid in patients with upper gastrointestinal bleeding.
  • To evaluate its impact on mortality, bleeding, surgery, and transfusion requirements.
  • To compare tranexamic acid with placebo and anti-ulcer drugs.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials.
  • Searches included major electronic databases up to October 2011.
  • All-cause mortality was the primary outcome, analyzed using random-effects models.

Main Results:

  • Meta-analysis of 7 trials (tranexamic acid vs. placebo/cimetidine/lansoprazole) showed reduced mortality with tranexamic acid versus placebo (RR: 0.61, 95% CI 0.42 to 0.89).
  • This mortality benefit was not robust in sensitivity and subgroup analyses.
  • No significant differences were observed for bleeding, surgery, or transfusion rates; thrombotic events were not significantly increased.

Conclusions:

  • Tranexamic acid is not recommended for routine use in upper gastrointestinal bleeding due to limitations in evidence validity.
  • Further trials are necessary to evaluate tranexamic acid in combination with standard treatments.
  • The role of tranexamic acid in managing upper gastrointestinal bleeding requires additional investigation.